Background:
Lung cancer is one of the leading causes of cancer mortality in the
US. The use of precision medicine in the past 10 years has
significantly changed the therapeutic landscape of lung cancer.
Management of advanced non-small cell lung cancer (NSCLC) has
transitioned from a chemotherapeutic approach to targeted treatments and
immunotherapeutic agents. Several tyrosine kinase inhibitors (TKIs) have
been approved for patients with targeted mutations while patients who do
not have driver mutations; immunotherapy has been recently approved as
frontline therapy,which has resulted in marked improvement in overall
survival and added a new tool in our armamentarium.